Skip to content

Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses (RETAIN).

Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses (RETAIN).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202605631926248
Enrollment
180
Registered
2026-05-19
Start date
2022-04-30
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

Enhanced adherence counselling or motivational interviewing
Basic adherence counselling.

Sponsors

Desmond Tutu Health Foundation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • =16 years old • Signed informed consent for RETAIN at enrolment into SUSTAIN • Enrolled onto the SUSTAIN study (meeting all eligibility criteria) • Flagged as poorly adherent by one of the three study adherence methodolgies • Able to sign written informed consent

Exclusion criteria

Exclusion criteria: • Unable to understand study procedures

Design outcomes

Primary

MeasureTime frame
The primary objective of RETAIN is to explore the more immediate impact of the adherence intervention on individual adherence behaviour through monitoring changes in daily dosing behaviour and drug concentrations (short and long half-life moieties) immediately before and shortly after the intervention is delivered (intra-individual analyses); as well as the immediate impact on viral load. The primary outcomes of RETAIN will include the change in 30-day daily dosing (using Wisepill®) immediately before and within 4 weeks after completion of the adherence intervention; and a change in drug concentrations (plasma tenofovir concentrations, and tenofovir diphosphate from dried blood spot sampling as well as presence of urine tenofovir using a new lateral flow assay) immediately before and within 4 weeks after completion of the adherence intervention (Figure 3 and Tables 1 and 2).

Secondary

MeasureTime frame
Secondary outcomes include the impact of the adherence intervention on viral load, as well as retention in care and viral suppression rates at month 12.

Countries

South Africa

Contacts

Public ContactTebogo Joy Mosina

Study coordinator

tebogo.mosina@hiv-research.org.za+27739445354

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026